Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Webinar: Using machine learning to identify adverse events from scientific literature
Posted on February 5th, 2020 by Umesh Nandal PhD in Pharmacovigilance
The “vigilance” aspect of the pharmacovigilance process can be very challenging. Always being on guard and knowing all of the places to look can be difficult. In a sea of information, it can even seem like a nearly impossible task to maintain awareness of all adverse events (AE). That is why there has been a lot of buzz around technologies that can help automate parts of the pharmacovigilance process.
(more…)Elsevier supports Amsterdam’s AI initiatives
Posted on January 29th, 2020 by Mark Siebert in Pharma R&D
Amsterdam, a vibrant and renowned cultural destination, has also been enlarging its reputation as an innovative scientific hub. A series of big new national initiatives, including the corporate Kickstart AI program and the academia-driven AI Technology for People initiative (which is making “AI for Health” one of its main priorities), have put the focus squarely on artificial intelligence.
(more…)Life Sciences trends that make me excited for 2020 (and beyond)
Posted on January 20th, 2020 by Umesh Nandal PhD in Pharma R&D
Beginning a new year offers an important opportunity to reflect on the past one. I’ve been thinking a lot about what I learned in 2019, and where I believe my industry is going as we continue further into 2020.
(more…)Amsterdam goes all-in on AI
Posted on January 17th, 2020 by Mark Siebert in Pharma R&D
Artificial intelligence are the words on everyone’s lips these days. Across industries, AI is driving some of today’s most exciting innovations and is poised to be ubiquitous in the future. But success in AI demands investment, and now is the time to put up those funds in order to secure the brightest minds and best companies. That’s why Amsterdam’s educational institutions and knowledge centers are joining forces and pledging one billion euros for AI.
(more…)
